Local angiotensin-converting enzyme 2 gene expression in kidney allografts is not affected by renin-angiotensin-aldosterone inhibitors

0542902 - MBÚ 2022 RIV CH eng J - Článek v odborném periodiku
Cahová, M. - Květoň, M. - Petr, V. - Funda, David P. - Daňková, H. - Viklický, O. - Hrubá, P.
Local angiotensin-converting enzyme 2 gene expression in kidney allografts is not affected by renin-angiotensin-aldosterone inhibitors.
Kidney & Blood Pressure Research. Roč. 46, č. 2 (2021), s. 245-249. ISSN 1420-4096. E-ISSN 1423-0143
Institucionální podpora: RVO:61388971
Klíčová slova: covid-19 * Angiotensin-converting enzyme 2 * Renin-angiotensin system inhibitors * Kidney
Obor OECD: Microbiology
Impakt faktor: 3.096, rok: 2021
Způsob publikování: Open access
https://www.karger.com/Article/Abstract/513710

Background: Preclinical studies suggested that pharmacological inhibition of the renin-angiotensin-aldosterone system (RAAS) by ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) may increase local angiotensin-converting enzyme 2 (ACE2) expression. Methods: In this study, we evaluated the effect of ACEi or ARB treatment on expression of ACE2, ACE, and AGTR1 in 3-month protocol kidney allograft biopsies of stable patients using RT-qPCR (n = 48). Protein ACE2 expression was assessed using immunohistochemistry from paraffin sections. Results: The therapy with RAAS blockers was not associated with increased ACE2, ACE, or ATGR1 expression in kidney allografts and also ACE2 protein immunohistochemistry did not reveal differences among groups. Conclusions: ACEis or ARBs in kidney transplant recipients do not affect local ACE2 expression. This observation supports long-term RAAS treatment in kidney transplant recipients, despite acute complications such as COVID-19 where ACE2 serves as the entry protein for infection.
Trvalý link: http://hdl.handle.net/11104/0320253